Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Weak functional connectivity in the human fetal brain prior to preterm birth.

Thomason ME, Scheinost D, Manning JH, Grove LE, Hect J, Marshall N, Hernandez-Andrade E, Berman S, Pappas A, Yeo L, Hassan SS, Constable RT, Ment LR, Romero R.

Sci Rep. 2017 Jan 9;7:39286. doi: 10.1038/srep39286.

2.

Focused grid-based resampling for protein docking and mapping.

Mamonov AB, Moghadasi M, Mirzaei H, Zarbafian S, Grove LE, Bohnuud T, Vakili P, Ch Paschalidis I, Vajda S, Kozakov D.

J Comput Chem. 2016 Apr 30;37(11):961-70. doi: 10.1002/jcc.24273. Epub 2016 Feb 2.

3.

The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins.

Kozakov D, Grove LE, Hall DR, Bohnuud T, Mottarella SE, Luo L, Xia B, Beglov D, Vajda S.

Nat Protoc. 2015 May;10(5):733-55. doi: 10.1038/nprot.2015.043. Epub 2015 Apr 9.

4.

Age-related increases in long-range connectivity in fetal functional neural connectivity networks in utero.

Thomason ME, Grove LE, Lozon TA Jr, Vila AM, Ye Y, Nye MJ, Manning JH, Pappas A, Hernandez-Andrade E, Yeo L, Mody S, Berman S, Hassan SS, Romero R.

Dev Cogn Neurosci. 2015 Feb;11:96-104. doi: 10.1016/j.dcn.2014.09.001. Epub 2014 Sep 27.

5.

Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies.

Forero-Torres A, Bartlett NL, Berryman RB, Chen R, Matous JV, Fanale MA, O'Connor OA, Olshefski R, Smith SE, Huebner D, Levine PL, Grove LE, Gopal AK.

Leuk Lymphoma. 2015 Apr;56(4):1151-3. doi: 10.3109/10428194.2014.951843. Epub 2014 Oct 7. No abstract available.

PMID:
25110824
6.

Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

Illidge T, Bouabdallah R, Chen R, Gopal AK, Moskowitz CH, Ramchandren R, Shustov AR, Tilly H, Trippett TM, Gibb A, Grove LE, Advani R.

Leuk Lymphoma. 2015 Mar;56(3):703-10. doi: 10.3109/10428194.2014.930852. Epub 2015 Jan 21.

PMID:
24913507
7.

CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.

Han TH, Gopal AK, Ramchandren R, Goy A, Chen R, Matous JV, Cooper M, Grove LE, Alley SC, Lynch CM, O'Connor OA.

J Clin Pharmacol. 2013 Aug;53(8):866-77. doi: 10.1002/jcph.116. Epub 2013 Jun 10.

8.

FTFlex: accounting for binding site flexibility to improve fragment-based identification of druggable hot spots.

Grove LE, Hall DR, Beglov D, Vajda S, Kozakov D.

Bioinformatics. 2013 May 1;29(9):1218-9. doi: 10.1093/bioinformatics/btt102. Epub 2013 Mar 7.

9.

Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia.

Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers EL, Jurcic JG.

Haematologica. 2013 Jan;98(1):119-28. doi: 10.3324/haematol.2012.066613. Epub 2012 Jul 16.

10.

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.

Gopal AK, Ramchandren R, O'Connor OA, Berryman RB, Advani RH, Chen R, Smith SE, Cooper M, Rothe A, Matous JV, Grove LE, Zain J.

Blood. 2012 Jul 19;120(3):560-8. doi: 10.1182/blood-2011-12-397893. Epub 2012 Apr 17.

11.

FTSite: high accuracy detection of ligand binding sites on unbound protein structures.

Ngan CH, Hall DR, Zerbe B, Grove LE, Kozakov D, Vajda S.

Bioinformatics. 2012 Jan 15;28(2):286-7. doi: 10.1093/bioinformatics/btr651. Epub 2011 Nov 22.

12.

Robust identification of binding hot spots using continuum electrostatics: application to hen egg-white lysozyme.

Hall DH, Grove LE, Yueh C, Ngan CH, Kozakov D, Vajda S.

J Am Chem Soc. 2011 Dec 28;133(51):20668-71. doi: 10.1021/ja207914y. Epub 2011 Dec 1.

13.

Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma.

Foyil KV, Kennedy DA, Grove LE, Bartlett NL, Cashen AF.

Leuk Lymphoma. 2012 Mar;53(3):506-7. doi: 10.3109/10428194.2011.614706. Epub 2011 Oct 10. No abstract available.

PMID:
21867368
14.

Structural conservation of druggable hot spots in protein-protein interfaces.

Kozakov D, Hall DR, Chuang GY, Cencic R, Brenke R, Grove LE, Beglov D, Pelletier J, Whitty A, Vajda S.

Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13528-33. doi: 10.1073/pnas.1101835108. Epub 2011 Aug 1.

15.

Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial.

Raza A, Jurcic JG, Roboz GJ, Maris M, Stephenson JJ, Wood BL, Feldman EJ, Galili N, Grove LE, Drachman JG, Sievers EL.

Leuk Lymphoma. 2009 Aug;50(8):1336-44. doi: 10.1080/10428190903050013.

PMID:
19557623
16.

Synthesis, X-ray crystallographic characterization, and electronic structure studies of a di-azide iron(III) complex: implications for the azide adducts of iron(III) superoxide dismutase.

Grove LE, Hallman JK, Emerson JP, Halfen JA, Brunold TC.

Inorg Chem. 2008 Jul 7;47(13):5762-74. doi: 10.1021/ic800073t. Epub 2008 Jun 6.

17.

Spectroscopic and computational investigation of second-sphere contributions to redox tuning in Escherichia coli iron superoxide dismutase.

Grove LE, Xie J, Yikilmaz E, Miller AF, Brunold TC.

Inorg Chem. 2008 May 19;47(10):3978-92. doi: 10.1021/ic702412y. Epub 2008 Apr 24.

18.

Spectroscopic and computational insights into second-sphere amino-acid tuning of substrate analogue/active-site interactions in iron(III) superoxide dismutase.

Grove LE, Xie J, Yikilmaz E, Karapetyan A, Miller AF, Brunold TC.

Inorg Chem. 2008 May 19;47(10):3993-4004. doi: 10.1021/ic702414m. Epub 2008 Apr 24.

19.

Angiogenic potential of 3-nitro-4-hydroxy benzene arsonic acid (roxarsone).

Basu P, Ghosh RN, Grove LE, Klei L, Barchowsky A.

Environ Health Perspect. 2008 Apr;116(4):520-3. doi: 10.1289/ehp.10885.

20.

How can a single second sphere amino acid substitution cause reduction midpoint potential changes of hundreds of millivolts?

Yikilmaz E, Porta J, Grove LE, Vahedi-Faridi A, Bronshteyn Y, Brunold TC, Borgstahl GE, Miller AF.

J Am Chem Soc. 2007 Aug 15;129(32):9927-40. Epub 2007 Jul 12.

PMID:
17628062
21.

Quantitative characterization of mitosis-blocked tetraploid cells using high content analysis.

Grove LE, Ghosh RN.

Assay Drug Dev Technol. 2006 Aug;4(4):421-42.

PMID:
16945015
22.

A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma.

Ross HJ, Hart LL, Swanson PM, Rarick MU, Figlin RA, Jacobs AD, McCune DE, Rosenberg AH, Baron AD, Grove LE, Thorn MD, Miller DM, Drachman JG, Rudin CM.

Lung Cancer. 2006 Oct;54(1):69-77. Epub 2006 Aug 28.

23.
24.

Promotion of growth and apoptosis in c-myc nullizygous fibroblasts by other members of the myc oncoprotein family.

Landay M, Oster SK, Khosravi F, Grove LE, Yin X, Sedivy J, Penn LZ, Prochownik EV.

Cell Death Differ. 2000 Aug;7(8):697-705.

25.

Genetic dissection of c-myc apoptotic pathways.

Nesbit CE, Tersak JM, Grove LE, Drzal A, Choi H, Prochownik EV.

Oncogene. 2000 Jun 29;19(28):3200-12.

26.

Differential apoptotic behaviors of c-myc, N-myc, and L-myc oncoproteins.

Nesbit CE, Grove LE, Yin X, Prochownik EV.

Cell Growth Differ. 1998 Sep;9(9):731-41.

Supplemental Content

Loading ...
Support Center